Back to results
US 2014/0178352 A1Published application
Peptide inhibitors of protein kinase c
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorDaria Mochly-Rosen
Life of this patent
Estimating the term…
Abstract
PKC V5 isozyme-specific peptides are described. The sequences and compositions comprising the sequences are useful for treating disease states associated with the PKC isozyme from which they are respectively derived. Methods of treatment, pharmaceutical formulations and methods of identifying compounds that mimic the activity of the peptides are also described.
Claims17
A method for protecting tissue from damage due to an ischemic or hypoxic event comprising:
- administering to a mammal in need thereof, a therapeutically effective amount of a peptide consisting of a contiguous sequence of six to twelve amino acid residues that is at least 80% identical to a contiguous sequence of six to twelve amino acid residues of a variable 5 (V5) domain of a delta protein kinase C (PKC) isozyme (SEQ ID NO:26), wherein the peptide inhibits delta PKC isozyme activity.
A method for treating cardiac hypertrophy and heart failure comprising:
- administering to a mammal in need thereof, a therapeutically effective amount of a peptide consisting of a contiguous sequence of six to twelve amino acid residues that is at least 80% identical to a contiguous sequence of six to twelve amino acid residues of a variable 5 (V5) domain of a βII protein kinase C (PKC) isozyme (SEQ ID NO:14), wherein the peptide inhibits βII PKC isozyme activity.
Dependencies are inferred from the claim text.